ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Astellas Reports XOSPATA, Azacitidine Combination Did Not Meet Endpoint americanpharmaceuticalreview
December 23, 2020Astellas Pharma announced that a Phase 3 trial of XOSPATA? (gilteritinib) plus azacitidine versus azacitidine alone in newly diagnosed FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia (AML) patients who were ineligible for intensive induction ...
Pharma Sources Insight January 2025
